Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM15P2G)

• Drug Name: (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol Drug Info
• Synonyms: Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol; YC-1

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5712
  ChEBI ID: CHEMBL333985
  CAS Number: CAS 170632-47-0
  TTD Drug ID: DM15P2G

Molecule-Related Drug Atlas

Drug(s) Targeting HIF1-alpha messenger RNA (HIF1A mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PT2385	DMCSN69	Recurrent glioblastoma	2A00.00	Phase 2	[7]
ISIS 298697	DM0WH1L	Discovery agent	N.A.	Investigative	[8]
ISIS 298744	DM8VMQ4	Discovery agent	N.A.	Investigative	[8]
ISIS 298746	DMHOJ0Z	Discovery agent	N.A.	Investigative	[8]
ISIS 298745	DM9YMPI	Discovery agent	N.A.	Investigative	[8]
ISIS 298743	DMD3NSQ	Discovery agent	N.A.	Investigative	[8]
ISIS 298702	DM4L7NE	Discovery agent	N.A.	Investigative	[8]
ISIS 298700	DM3DE98	Discovery agent	N.A.	Investigative	[8]
ISIS 175510	DMPAXR4	Discovery agent	N.A.	Investigative	[8]
ISIS 298699	DMB28JW	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Soluble guanylate cyclase (GCS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[9]
Nitroglycerin	DMQ2491	Angina pectoris	BA40	Approved	[3]
Sodium nitroprusside	DMGA9X0	Hypertension	BA00-BA04	Approved	[10]
IW-1973	DMK2T7J	Heart failure	BD10-BD13	Phase 2	[11]
CTI-1601	DMM4JMB	Friedreich's ataxia	8A03.10	Phase 2	[12]
Runcaciguat	DMCFTTN	Chronic kidney disease	GB61	Phase 2	[13]
MK-5475	DMIIZ4R	Pulmonary arterial hypertension	BB01.0	Phase 2	[14]
CY6463	DM84AVQ	Alzheimer disease	8A20	Phase 2	[15]
CY6463	DM84AVQ	Alzheimer disease	8A20	Phase 2	[16]

Drug(s) Affected By Mitogen-activated protein kinase 8 (MAPK8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[17]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[18]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[19]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[20]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[21]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[22]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[23]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[24]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[21]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[25]

Drug(s) Affected By cGMP-dependent protein kinase 1 (PRKG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[28]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[29]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[30]
Methamphetamine	DMPM4SK	Anxiety		Approved	[31]
EXISULIND	DMBY56U	Colorectal cancer	2B91.Z	Phase 3	[4]
CP-461	DMEYMTX	Inflammatory bowel disease	DD72	Phase 2	[4]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
Geldanamycin	DMS7TC5	Kidney cancer	2C90.0	Discontinued in Phase 2	[33]

Drug(s) Affected By Cytochrome c (CYCS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[34]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[35]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[36]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[37]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[38]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[39]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[40]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[41]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[42]
Pefloxacin	DM49IGF	Gonococcal urethritis	1A70.0Y	Approved	[43]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HIF1-alpha messenger RNA (HIF1A mRNA)	TTSN6QU	HIF1A_HUMAN	Inhibitor	[2]
Soluble guanylate cyclase (GCS)	TT23PYC	GCYA1_HUMAN; GCYB1_HUMAN	Activator	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
cGMP-dependent protein kinase 1 (PRKG1)	OTPAS4LF	KGP1_HUMAN	Gene/Protein Processing	[4]
Cytochrome c (CYCS)	OTBFALJD	CYC_HUMAN	Protein Interaction/Cellular Processes	[5]
Mitogen-activated protein kinase 8 (MAPK8)	OTEREYS5	MK08_HUMAN	Gene/Protein Processing	[6]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5291).
• [2] Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6305-10.
• [3] Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):8-14.
• [4] Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells. J Pharmacol Exp Ther. 2001 Nov;299(2):583-92.
• [5] Combined application of camptothecin and the guanylate cyclase activator YC-1: Impact on cell death and apoptosis-related proteins in ovarian carcinoma cell lines. Chem Biol Interact. 2009 Oct 7;181(2):185-92. doi: 10.1016/j.cbi.2009.05.013. Epub 2009 May 27.
• [6] Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin Cancer Res. 2000 Oct;6(10):4136-41.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
• [9] Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Am J Cardiol. 1996 May 30;77(13):2C-7C.
• [10] Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Crit Care Res Pract.2012;2012:290805.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases. Front Pharmacol. 2021 May 24;12:656561.
• [13] Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2021 Dec;394(12):2363-2379.
• [14] Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH). Respir Med. 2023 Jan;206:107065.
• [15] First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator. Clin Transl Sci. 2023 Aug;16(8):1381-1395.
• [16] Clinical pipeline report, company report or official report of Cyclerion Therapeutics
• [17] Cisplatin induces autophagy to enhance hepatitis B virus replication via activation of ROS/JNK and inhibition of the Akt/mTOR pathway. Free Radic Biol Med. 2019 Feb 1;131:225-236. doi: 10.1016/j.freeradbiomed.2018.12.008. Epub 2018 Dec 11.
• [18] Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
• [19] Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
• [20] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [21] Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT116 cells. J Biol Chem. 2002 Nov 15;277(46):43648-58. doi: 10.1074/jbc.M203214200. Epub 2002 Sep 6.
• [22] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [23] Lon protease and eiF2 are involved in acute, but not prolonged, antiretroviral induced stress response in HepG2 cells. Chem Biol Interact. 2016 May 25;252:82-6. doi: 10.1016/j.cbi.2016.03.021. Epub 2016 Apr 1.
• [24] Disease-modifying effects of glucosamine HCl involving regulation of metalloproteinases and chemokines activated by interleukin-1beta in human primary synovial fibroblasts. J Cell Biochem. 2008 May 1;104(1):38-50. doi: 10.1002/jcb.21597.
• [25] Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine. Cancer Sci. 2003 Oct;94(10):886-93.
• [26] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [27] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [28] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [29] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [30] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [31] Genome-wide association for methamphetamine dependence: convergent results from 2 samples. Arch Gen Psychiatry. 2008 Mar;65(3):345-55. doi: 10.1001/archpsyc.65.3.345.
• [32] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [33] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [34] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [35] Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1. Mol Endocrinol. 2010 May;24(5):969-80. doi: 10.1210/me.2009-0148. Epub 2010 Mar 8.
• [36] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [37] Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
• [38] K-RAS transformation in prostate epithelial cell overcomes H2O2-induced apoptosis via upregulation of gamma-glutamyltransferase-2. Toxicol In Vitro. 2012 Apr;26(3):429-34. doi: 10.1016/j.tiv.2012.01.013. Epub 2012 Jan 17.
• [39] Nitric oxide inhibits execution of apoptosis at two distinct ATP-dependent steps upstream and downstream of mitochondrial cytochrome c release. Biochem Biophys Res Commun. 1999 Apr 29;258(1):215-21. doi: 10.1006/bbrc.1999.0491.
• [40] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [41] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [42] Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
• [43] Under ambient UVA exposure, pefloxacin exhibits both immunomodulatory and genotoxic effects via multiple mechanisms. J Photochem Photobiol B. 2018 Jan;178:593-605. doi: 10.1016/j.jphotobiol.2017.12.014. Epub 2017 Dec 15.